 PURCHASE, N.Y., Oct. 08, 2021 GLOBE NEWSWIRE -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina the Company or Cognition, today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of 12.00 per share. All of the shares of common stock are being offered by Cognition. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cognition, are expected to be approximately 45.2 million. 